×
Kintara Therapeutics Net Profit Margin 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Kintara Therapeutics net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Kintara Therapeutics Net Profit Margin 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Kintara Therapeutics net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$172.8B
Vertex Pharmaceuticals (VRTX)
$124.7B
Regeneron Pharmaceuticals (REGN)
$109.2B
Gilead Sciences (GILD)
$108B
Bristol Myers Squibb (BMY)
$107.9B
CSL (CSLLY)
$97.9B
GSK (GSK)
$79.9B
Alnylam Pharmaceuticals (ALNY)
$38B
Argenex SE (ARGX)
$33.8B
Biogen (BIIB)
$27.7B
BioNTech SE (BNTX)
$26.6B
Illumina (ILMN)
$23.3B
BeiGene (BGNE)
$21.3B
Moderna (MRNA)
$20.8B
Genmab (GMAB)
$15.2B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$13.3B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
Incyte (INCY)
$12.8B
Sarepta Therapeutics (SRPT)
$12.1B
Bio-Techne Corp (TECH)
$11.3B
QIAGEN (QGEN)
$9.8B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.8B
Revolution Medicines (RVMD)
$8.4B
Intra-Cellular Therapies (ITCI)
$8.3B
Exelixis (EXEL)
$8.2B
Repligen (RGEN)
$8.2B
Ascendis Pharma (ASND)
$7.9B